Tingsn Announces NMPA Approval and FDA Clearance of TINGSN FINDERS 2, Accelerating Global Expansion

TINGSN FINDERS 2Color Doppler Ultrasound Diagnostic SystemOfficially passed the registration certification of the National Medical Products Administration (NMPA) (Registration No. 20253061465), marking that the productMeets China's strict standards for medical devices and can be officially put into use in the Chinese market.As a Doppler ultrasound device that supports intracardiac ultrasound diagnosis, TINGSN FINDERS 2 demonstrates excellent compatibility and can be used with TINGSN Sonic Eyes 10.TINGSN Sonic Eyes 10 Eco、TINGSN Sonic Eyes 10 Pro Three Types of Intracardiac Echocardiography (ICE) Catheters PerfectAdaptation.

This extensive compatibility provides doctors with more flexible and efficient intracavitary imaging, meeting the usage needs and habits of different clinical settings, and significantly enhancing TINGSN's competitiveness and service capabilities in the Chinese market.

TINGSN FINDERS 2 recently obtained FDA certification, compatible with the intracardiac ultrasound probe TINGSN Sonic Eyes 10 Eco. FDA certification signifies that the product has reached internationally top-tier standards in design, performance, and safety. This is not only a robust endorsement of TINGSN's R&D capabilities but also serves as a "stepping stone" for the product to enter the international high-end market, particularly paving the way for entry into the U.S. market. It allows medical innovations from "Made in China" to have the opportunity to serve a broader global patient population.

With the dual approval of NMPA and FDA, TINGSN FINDERS 2 officially launches its synchronized sales strategy in both domestic and overseas markets. In China, it rapidly penetrates the market based on existing layouts, accelerating the popularity and advancement of cardiovascular diagnostic equipment. Overseas, leveraging FDA certification as a pivot, it actively expands its global cooperation network, gradually increasing its international market share, allowing "Made in China" to benefit more patients across countries and regions. This dual-track strategy marks a substantive breakthrough in TINGSN's globalization plan and demonstrates the confidence and strength of Chinese medical technology companies rooted in their home base while reaching out to the world.